MARY  ESTES  to  Viral Vaccines
                            
                            
                                This is a "connection" page, showing publications  MARY  ESTES  has written about  Viral Vaccines.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            4.691
         
        
        
     
 
    
        
        - 
            Norovirus replication, host interactions and vaccine advances. Nat Rev Microbiol. 2025 Jun; 23(6):385-401.
            
            
                Score: 0.738
             
- 
            A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
            
            
                Score: 0.704
             
- 
            Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
            
            
                Score: 0.525
             
- 
            Norovirus vaccine development: next steps. Expert Rev Vaccines. 2012 Sep; 11(9):1023-5.
            
            
                Score: 0.313
             
- 
            Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
            
            
                Score: 0.183
             
- 
            Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol. 2003 Sep; 108(3):241-7.
            
            
                Score: 0.168
             
- 
            Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol. 2001 Oct; 75(20):9713-22.
            
            
                Score: 0.147
             
- 
            Norwalk virus vaccines: challenges and progress. J Infect Dis. 2000 May; 181 Suppl 2:S367-73.
            
            
                Score: 0.133
             
- 
            Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018 10; 31(5):422-432.
            
            
                Score: 0.119
             
- 
            Viral gastroenteritis. Lancet. 2018 07 14; 392(10142):175-186.
            
            
                Score: 0.117
             
- 
            Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol. 1998 Feb; 72(2):1345-53.
            
            
                Score: 0.114
             
- 
            Prospects and Challenges in the Development of a Norovirus Vaccine. Clin Ther. 2017 Aug; 39(8):1537-1549.
            
            
                Score: 0.110
             
- 
            B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Clin Vaccine Immunol. 2017 May; 24(5).
            
            
                Score: 0.108
             
- 
            Advances in molecular biology: impact on rotavirus vaccine development. J Infect Dis. 1996 Sep; 174 Suppl 1:S37-46.
            
            
                Score: 0.103
             
- 
            Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996 Sep; 174 Suppl 1:S88-92.
            
            
                Score: 0.103
             
- 
            Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog. 2016 04; 12(4):e1005334.
            
            
                Score: 0.101
             
- 
            Rotavirus subunit vaccines. Arch Virol Suppl. 1996; 12:199-206.
            
            
                Score: 0.099
             
- 
            Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Clin Vaccine Immunol. 2016 02; 23(2):181-3.
            
            
                Score: 0.098
             
- 
            Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
            
            
                Score: 0.095
             
- 
            Rotavirus vaccines and vaccination potential. Curr Top Microbiol Immunol. 1994; 185:285-337.
            
            
                Score: 0.086
             
- 
            Rotavirus vaccine administered parenterally induces protective immunity. J Virol. 1993 Nov; 67(11):6633-41.
            
            
                Score: 0.085
             
- 
            Rotaviruses: cause of vaccine-preventable disease yet many fundamental questions remain to be explored. Curr Opin Virol. 2012 Aug; 2(4):369-72.
            
            
                Score: 0.077
             
- 
            Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
            
            
                Score: 0.074
             
- 
            Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J. 2006 Jul; 4(4):419-32.
            
            
                Score: 0.051
             
- 
            Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol. 1999 Jun; 73(6):4813-22.
            
            
                Score: 0.031
             
- 
            Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol. 1998 Nov; 72(11):9233-46.
            
            
                Score: 0.030
             
- 
            Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol. 1998 Apr; 72(4):3390-3.
            
            
                Score: 0.029
             
- 
            Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol. 1997 Nov; 71(11):8707-17.
            
            
                Score: 0.028
             
- 
            Virus-like particle vaccines for mucosal immunization. Adv Exp Med Biol. 1997; 412:387-95.
            
            
                Score: 0.026
             
- 
            Antiviral targets of human noroviruses. Curr Opin Virol. 2016 06; 18:117-25.
            
            
                Score: 0.025
             
- 
            Recombinant Norwalk virus-like particles as an oral vaccine. Arch Virol Suppl. 1996; 12:243-9.
            
            
                Score: 0.025
             
- 
            Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15; 211(6):870-8.
            
            
                Score: 0.022
             
- 
            Molecular biology and immunology of rotavirus infections. Immunol Invest. 1989 Jan-May; 18(1-4):571-81.
            
            
                Score: 0.015
             
- 
            Analysis of host range restriction determinants in the rabbit model: comparison of homologous and heterologous rotavirus infections. J Virol. 1998 Mar; 72(3):2341-51.
            
            
                Score: 0.007